RxDoctor Payments Data

Fred Khalouf, DO

Interventional Pain Medicine · Altoona, PANPI 1013960277

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Nevro Corp. accounts for 63.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $685 and has fallen 86.0% since, to $96 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in PA, where the typical reported total is $2,714.

$2,221in general payments, 2019–2025

Across 60 payments — averaging $37.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$1K
  • Medtronic$393
  • Amgen$288
  • Globus Medical$81
  • Abbott$23
  • Vertex$15
  • plus $2 from 1 others
$487,708in research payments, 2019–2025

Across 69 payments — averaging $7068.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanos Medical$488K

What the payments were for

  • Food & beverage$2,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nevro Corp.42$1,419
Medtronic10$393
Amgen(2 entities)3$288
Globus Medical2$81
Abbott1$23
Vertex1$15
GRT US Holding, Inc.1$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,221 in reported general payments places this provider in the 45th percentile of 59 interventional pain medicine providers in Pennsylvania.

See all interventional pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$336,975
Medicare patients
568
Services billed
6,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin844$9,521
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$1,650
Celecoxib62$1,332
Baclofen56$915
Tramadol Hcl171$883
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen37$754
Oxycodone Hcl12$384
Meloxicam111$353
Duloxetine Hcl24$314
Prednisone81$279
Tizanidine Hcl31$269
Cyclobenzaprine Hcl34$199
Doxycycline Hyclate36$131
Amitriptyline Hcl13$90

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →